Exercise Intolerance
13
2
3
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (13)
Sports Shoes and the Six-Minute Walk Test in COPD
Predictive Factors of Response to Phase II Cardiac Rehabilitation in Heart Failure With Reduced Ejection Fraction
Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19
Effects of Breathing Training and Nitrate on Exercise at Simulated Altitude
Restoring Energy With Sub-symptom Threshold Optimized Rehabilitation Exercise for Long COVID
Muscle Weakness in COVID-19 Patients
The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
Long COVID and Post-exertional Pulmonary Diffusion
Heat Therapy and Muscle Function Study
Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance
Effects of Rehabilitation in Patients With Stable Chronic Heart Failure
CAN BREATHE in COPD Trial
Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction